Treatment: adult patients with first-time multiform glioblastoma accompanied by radiotherapy and then as monotherapy; children aged 3 years and adult patients with malignant glioma in the form of multiformal glioblastoma or anaplastic astrocytoma in the presence of relapse or disease progression after standard therapy.
Composition and form of release
Active ingredient: temozolomide.
Temomedak is produced in capsules of 20 milligrams.
This is a drug with anticancer activity. It is used for oncological diseases of the nervous system (in particular, the brain).
Temomedak is indicated for the treatment of adult patients with glioblastoma multiforme (in combination with radiotherapy or as monotherapy), as well as adults and children over three years of age with malignant glioma, anaplastic astrocytoma (with relapses, disease progression after standard treatment).
The use of Temomedac is prohibited in case of hypersensitivity to this drug, in the presence of signs of severe myelosuppression (suppression of bone marrow hematopoiesis).
Not applicable to children under three years of age.
Application during pregnancy and lactation
Do not use the medicine in pregnant women. Women of reproductive age need to use reliable methods of contraception when therapy with this drug.
During treatment with this pharmaceutical preparation, breastfeeding must be stopped.
Method of administration and dosage
Therapy with this drug can only be carried out by a doctor with experience in treating the above-mentioned oncological diseases. Therapy is selected depending on the disease and the patient’s age. So, for adult patients with newly diagnosed glioblastoma multiforme, the drug is used daily orally at a dose of 75 mg / m2 for 42 days, accompanied by radiotherapy; followed by a course of monotherapy (adjuvant therapy) for six cycles. In each cycle, the drug is applied for five consecutive days, followed by a 23-day break.
The maximum duration of therapy is two years. If signs of disease progression occur, this drug should be discontinued.
The drug is taken on an empty stomach, one hour before meals. The capsules are taken orally whole, they cannot be chewed or opened; should be taken with one glass of water.
The drug has a dose-dependent hematological toxicity (the higher the dose of a given antitumor agent, the more pronounced blood disorders).
In case of an overdose, pancytopenia (a decrease in the number of all blood cells), pyrexia (fever), multiorgan failure are observed; with a significant overdose, there is a high probability of death.
In case of an overdose with this pharmaceutical, a hematological study should be performed; maintenance therapy is indicated.
The most common adverse reactions with this medication are nausea, fatigue, vomiting, anorexia, constipation, and headache. The development of seizures and rashes in patients was very often reported. Also, when using this drug, the following side effects may be observed: infections (including herpes simplex, candidiasis), weight loss, dizziness, anxiety, a decrease in the number of blood cells (anemia, neutropenia, leukopenia, thrombocytopenia, leukopenia, lymphopenia), hemorrhages on the skin, emotional lability, dry eyes, insomnia, blurred vision, edema, alopecia (baldness), arthralgia (joint pain), sweating, back pain, urinary disorders (including incontinence), chills, allergic reactions, impotence in men, pain in the mammary glands and amenorrhea and / or metrorrhagia in women.
There may also be an increase in the activity of hepatic transaminases (liver enzymes).
Storage conditions and periods
The shelf life of Temomedak is three years.
Capsules must be stored at temperatures up to +30 ° C.
Store the medicine out of the reach of children.